Figure 4

DSRCT have evidence of nuclear immuno-reactivity of p53 and evidence of MDM2/ MDM4 copy- number amplification in DSRCT. (A) % of cells with p53 nuclear immuno-reactivity in five samples of DSRCT stained with anti-p53. The number of cells with nuclear localization of p53 was scored in at least five (5–10) independent fields (20× magnification). Values represent mean ± SEM. (B) Representative image of DSRCT sample with anti-p53 immuno-staining. Arrows depict examples of cells with nuclear p53 staining. (C) MDM2/MDM4 copy number analysis as determined by qPCR in 15 primary DSRCT tumors (#1-15). Data represent the copy number (average and standard deviation) for each sample relative to a normal female blood DNA control (normal control) and the T778 liposarcoma cell line that has MDM2 amplification. Real-time quantitative PCR was performed using primers for MDM2, MDM4, or a non-amplified region of Chr17 (as an internal normalisation control for each sample).